Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.54 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.54 |
| ▸ | IKBKB | O14920 | 12/20 | 0.49 |
| ▸ | DKK1 | O94907 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.42 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633110 | 0.89 | IKBKB (0.47) | PIM1PIM2IKBKBDKK1GSK3B | |
| SCHEMBL1632840 | 0.85 | IKBKB (0.48) | IKBKBDKK1GSK3BCA1CA2 | |
| SCHEMBL1633082 | 0.83 | IKBKB (0.45) | PIM1PIM2IKBKBDKK1GSK3B | |
| SCHEMBL1632692 | 0.80 | IKBKB (0.47) | IKBKBDKK1GSK3BCA1CA2 | |
| SCHEMBL1632977 | 0.80 | IKBKB (0.53) | PIM1IKBKBDKK1GSK3BCA1 | |
| SCHEMBL13498293 | 0.79 | IKBKB (0.41) | PIM1PIM2IKBKBDKK1GSK3B | |
| SCHEMBL1632522 | 0.78 | DKK1 (0.51) | IKBKBDKK1GSK3BCA1CA2 | |
| SCHEMBL12724196 | 0.78 | IKBKB (0.51) | IKBKBDKK1GSK3BCA1CA2 | |
| SCHEMBL1633248 | 0.77 | IKBKB (0.53) | IKBKBDKK1GSK3BCA1CA2 | |
| SCHEMBL1631112 | 0.77 | IKBKB (0.59) | IKBKBDKK1GSK3BCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | PIM1 395/4885PIM2 440/4885IKBKB 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.